• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CryoPort Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/10/25 9:00:27 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYRX alert in real time by email
    false 0001124524 0001124524 2025-06-06 2025-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

      

    FORM 8-K

     

    CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 6, 2025

     

    CRYOPORT, INC. 

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-34632   88-0313393
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)
             

    112 Westwood Place, Suite 350

     Brentwood, TN 37027

    (Address of principal executive offices, including zip code)
             
    Registrant’s telephone number, including area code: (949) 470-2300
     
    Not Applicable
    (Former name or former address, if changed since last report)

      

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
         
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
         
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
         

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which
    registered
    Common Stock, $0.001 par value   CYRX   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

      

     

     

     

    Item 5.07Submission of Matters to a Vote of Security Holders.

     

    On June 6, 2025, Cryoport, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for the proposals submitted to a vote of stockholders at the Annual Meeting, each of which is described in detail in the Company’s proxy statement filed with the U.S. Securities and Exchange Commission on April 25, 2025 (“Proxy Statement”), are set forth below.

     

    Proposal No. 1: Election of Directors. The individuals listed below were elected to serve as directors of the Company until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or their earlier death, resignation, or removal:

     

    Director Nominee

    Votes For

    Votes Withheld

    Broker Non-Votes

    Linda Baddour 35,239,403 4,653,061 3,844,856
    Daniel M. Hancock 39,535,584 356,880 3,844,856
    Robert Hariri, M.D., Ph.D. 38,422,159 1,470,305 3,844,856
    Ram M. Jagannath 39,306,265 586,199 3,844,856
    Ramkumar Mandalam, Ph.D. 38,370,448 1,522,016 3,844,856
    Jerrell W. Shelton 39,476,173 416,291 3,844,856

     

    Proposal No. 2: Ratification of the appointment of Deloitte and Touche LLP as the independent registered public accounting firm of the Company and its subsidiaries for the year ending December 31, 2025. This proposal was approved as set forth below:

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    36,599,870 14,542 123,890 —

     

     

    Proposal No. 3: Advisory vote to approve the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. This proposal was approved as set forth below:

     

    Votes For

    Votes Against

    Abstentions

    Broker Non-Votes

    31,308,283 1,549,637 35,526 3,844,856

     

     

    Proposal No. 4: Advisory vote to approve the preferred frequency of future advisory votes on the compensation of the named executive officers. This proposal was approved as set forth below:

     

    1 Year

    2 Years

    3 Years

    Abstentions

    Broker Non-Votes

    31,819,718 311,644 733,429 28,655 3,844,856

     

     

    After considering the results of the vote of the stockholders on Proposal No. 4 and consistent with the recommendation of the Company’s Board of Directors, the Company will include a non-binding stockholder advisory vote to approve the compensation of its named executive officers in its proxy materials every year until the next required vote on the frequency of stockholder votes on named executive officer compensation.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 10, 2025 Cryoport, Inc.
       
      /s/ Robert Stefanovich
      Robert Stefanovich
      Chief Financial Officer

     

     

     

    Get the next $CYRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYRX

    DatePrice TargetRatingAnalyst
    8/6/2025Sector Weight → Overweight
    KeyBanc Capital Markets
    8/6/2025$16.00Market Perform → Outperform
    Leerink Partners
    7/22/2025$13.00Overweight
    Stephens
    3/24/2025$10.00Neutral → Buy
    UBS
    12/19/2024$11.00Buy
    Guggenheim
    12/19/2024$11.00Buy
    Canaccord Genuity
    8/7/2024$20.00 → $8.00Buy → Hold
    Jefferies
    7/31/2024$19.00 → $15.00Neutral → Buy
    B. Riley Securities
    More analyst ratings

    $CYRX
    SEC Filings

    View All

    SEC Form 10-K filed by CryoPort Inc.

    10-K - Cryoport, Inc. (0001124524) (Filer)

    3/5/26 4:53:43 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CryoPort Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cryoport, Inc. (0001124524) (Filer)

    3/3/26 5:10:46 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CryoPort Inc.

    SCHEDULE 13G/A - Cryoport, Inc. (0001124524) (Subject)

    2/17/26 5:00:26 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

    FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for th

    3/3/26 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd

    2/17/26 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

    Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology. This self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN₂) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designe

    2/11/26 8:30:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cryoport upgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets upgraded Cryoport from Sector Weight to Overweight

    8/6/25 7:50:22 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Cryoport from Market Perform to Outperform and set a new price target of $16.00

    8/6/25 7:21:40 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens resumed coverage on Cryoport with a new price target

    Stephens resumed coverage of Cryoport with a rating of Overweight and set a new price target of $13.00

    7/22/25 7:52:13 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mandalam Ramkumar sold $115,540 worth of shares (11,570 units at $9.99), decreasing direct ownership by 13% to 80,758 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    12/12/25 5:30:13 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hariri Robert J exercised 50,000 shares at a strike of $2.66 and sold $242,738 worth of shares (25,000 units at $9.71), increasing direct ownership by 95% to 51,275 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    9/12/25 5:30:14 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hariri Robert J sold $43,000 worth of shares (5,000 units at $8.60), decreasing direct ownership by 16% to 26,275 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    8/29/25 6:46:12 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Financials

    Live finance-specific insights

    View All

    Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

    FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for th

    3/3/26 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd

    2/17/26 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Reports Third Quarter 2025 Financial Results

    Third quarter revenue increased 15% year-over-year to $44.2 millionCommercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 millionLife Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-yearCompany updates full year 2025 revenue guidance of $170 to $174 millionNASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025. Provided in

    11/4/25 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Leadership Updates

    Live Leadership Updates

    View All

    Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

    Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i

    1/14/25 8:30:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Announces Appointment of Linda Baddour to its Board of Directors

    NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She

    3/3/21 4:08:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Appoints Martin Schmieg to Board of Directors

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L

    12/1/20 6:30:00 AM ET
    $BCTX
    $CLBS
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Managed Health Care

    $CYRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CryoPort Inc.

    SC 13G - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 4:02:52 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

    SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 1:34:13 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

    SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/13/24 7:16:51 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care